Deloitte.Digital



Agentic Al for CRM:

The next evolution of consumer engagement

The pharmaceutical industry is undergoing a transformation as companies search for improved efficiencies and stronger relationships with consumers. Achieving these goals may require a holistic reimagining of the customer engagement ecosystem, from the fundamentals of CRM infrastructure to the innovative layering of automation into all aspects of how companies connect with their audiences.

There has never been a better time to undertake this challenge, especially as artificial intelligence (AI) becomes ever more sophisticated in its ability to take the lead on defined tasks within the workflow.

For example, pharma companies can now leverage the power of Al agents (also known as agentic Al), which are tools that can autonomously analyze situations, make decisions, and adapt to future goals without direct human intervention. In essence, they are a digital workforce with their own targeted personas, able to interpret needs, complete actions, and adjust to circumstances similarly to a human member of staff.

It's a brand-new paradigm for customer engagement with exciting possibilities for both front-end and back-end operations.



Automated workflows

Al agents can handle routine back-office functions, such as account updating, roster management, and territory maps to free up human talent for more complex tasks.



Efficient field engagement

Repetitive administrative activities like pre-call planning and interaction logging can be delegated to AI agents, eliminating these tasks from the rep's daily workflow.



Personalized interactions and communications

With AI agents managing and augmenting routine communications tasks, reps can devote more time to critical interactions with the right people, providing a personalized yet consistent experience for customers.



AI Driven Sales Operations

Al agents can streamline sales operations by orchestrating the results from Al and data science models; e.g., dynamic call planning, micro-segmentation, field suggestions and thereby enabling autonomous "last-mile delivery" to the field. As Al agents mature over the next two to five years, now is the time to start laying the groundwork for an interconnected environment where reps and tailored Al agents co-exist to support customer relationships.



Set the vision

Start by crafting a future-state, end-to-end vision that clearly identifies opportunities for AI agents to address current pain points, eliminate potential inefficiencies, and maximize the value of the hybrid workforce.



Build the digital foundation

Pharma companies should plan for agentic AI integration in their choice of infrastructure options while assessing, collecting, and cleansing the data assets necessary to train AI models and fine tune AI agents ahead of deployment.



Prepare the workforce

Deploy employee-focused programs to infuse knowledge, promote buy-in, and encourage positive cultural shifts that showcase the value of AI agents for enhancing the CRM workflow, not replacing the need for the unique skills of human staff.



Deploy proofs of concept

To help ensure buy-in and adoption across the organization and prove ROI to key stakeholders, organizations should launch well-defined pilots in high-priority use cases that can clearly demonstrate the impact of AI agents on key pain points.

By taking a strategic approach to infusing the current customer engagement management process with future-ready AI agents, pharma companies can smoothly and successfully transform into more efficient, value-driven organizations with the capacity to develop and maintain relationships that produce meaningful and measurable results.

Deloitte.Digital

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

This publication contains general information only and Deloitte is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor. Deloitte shall not be responsible for any loss sustained by any person who relies on this publication.